Afrezza® INHALE-1 Study in Pediatrics
Trial details
- Registry ID
- NCT04974528
- Phase
- Phase 3
Drug identity checked against registry records
Also recorded as Abasaglar®; Basaglar®; Lantus®; Levemir®; Semglee®; Toujeo®; Tresiba®; insulin degludec; insulin detemir; insulin glargine
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Afrezza® INHALE-1 Study in PediatricsNCT04974528 | Mannkind Corporation | Phase 3 | Completed | 2024-10-03Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |